Recurrence rate in early-stage epithelial ovarian cancer: Is there a role for upfront maintenance with PARP inhibitors in stages I and II?
Objective: To determine the recurrence rate and survival among early-stage epithelial ovarian cancer cases considering homologous recombination deficiency (HRD) status. Methods: Single institution retrospective study of stage I/II EOC patients from 2017 to 2020. HRD was defined as evidence of germli...
Saved in:
Main Authors: | Monica D. Levine (Author), David M. O'Malley (Author), Paulina J. Haight (Author), Leigha Senter (Author), Vincent Wagner (Author), Kristin L. Bixel (Author), David E. Cohn (Author), Larry J. Copeland (Author), Casey M. Cosgrove (Author), Eric M. McLaughlin (Author), Floor J. Backes (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2023-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Use of the Khorana score to predict venous thromboembolism in patients undergoing chemotherapy for uterine cancer
by: Rachael N. Piver, et al.
Published: (2023) -
Wound complications following vulvar excision for nonmalignant lesionsAJOG Global Reports at a Glance
by: Glenn P. Boyles, MD, et al.
Published: (2021) -
High pre-treatment neutrophil-to-lymphocyte ratio as a prognostic marker for worse survival in patients with recurrent/metastatic cervical cancer treated with immune checkpoint inhibitors
by: Corinne A. Calo, et al.
Published: (2022) -
Acute worsening of dermatomyositis after initiation of PARP inhibitor therapy in two women with advanced ovarian malignancy
by: Stephen M. Graves, et al.
Published: (2021) -
Combination lenvatinib plus pembrolizumab in the treatment of ovarian clear cell carcinoma: A case series
by: Corinne A. Calo, et al.
Published: (2023)